560 related articles for article (PubMed ID: 12839971)
1. SU5416 and SU6668 attenuate the angiogenic effects of radiation-induced tumor cell growth factor production and amplify the direct anti-endothelial action of radiation in vitro.
Abdollahi A; Lipson KE; Han X; Krempien R; Trinh T; Weber KJ; Hahnfeldt P; Hlatky L; Debus J; Howlett AR; Huber PE
Cancer Res; 2003 Jul; 63(13):3755-63. PubMed ID: 12839971
[TBL] [Abstract][Full Text] [Related]
2. Combination of vascular endothelial growth factor receptor/platelet-derived growth factor receptor inhibition markedly improves radiation tumor therapy.
Timke C; Zieher H; Roth A; Hauser K; Lipson KE; Weber KJ; Debus J; Abdollahi A; Huber PE
Clin Cancer Res; 2008 Apr; 14(7):2210-9. PubMed ID: 18381963
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of vascular endothelial growth factor-associated tyrosine kinase activity with SU5416 blocks sprouting in the microvascular endothelial cell spheroid model of angiogenesis.
Haspel HC; Scicli GM; McMahon G; Scicli AG
Microvasc Res; 2002 May; 63(3):304-15. PubMed ID: 11969307
[TBL] [Abstract][Full Text] [Related]
4. SU6668 is a potent antiangiogenic and antitumor agent that induces regression of established tumors.
Laird AD; Vajkoczy P; Shawver LK; Thurnher A; Liang C; Mohammadi M; Schlessinger J; Ullrich A; Hubbard SR; Blake RA; Fong TA; Strawn LM; Sun L; Tang C; Hawtin R; Tang F; Shenoy N; Hirth KP; McMahon G; Cherrington
Cancer Res; 2000 Aug; 60(15):4152-60. PubMed ID: 10945623
[TBL] [Abstract][Full Text] [Related]
5. Vascular endothelial growth factor-toxin conjugate specifically inhibits KDR/flk-1-positive endothelial cell proliferation in vitro and angiogenesis in vivo.
Ramakrishnan S; Olson TA; Bautch VL; Mohanraj D
Cancer Res; 1996 Mar; 56(6):1324-30. PubMed ID: 8640821
[TBL] [Abstract][Full Text] [Related]
6. The angiogenesis inhibitor SU5416 has long-lasting effects on vascular endothelial growth factor receptor phosphorylation and function.
Mendel DB; Schreck RE; West DC; Li G; Strawn LM; Tanciongco SS; Vasile S; Shawver LK; Cherrington JM
Clin Cancer Res; 2000 Dec; 6(12):4848-58. PubMed ID: 11156244
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of vascular endothelial growth factor receptor signaling leads to reversal of tumor resistance to radiotherapy.
Geng L; Donnelly E; McMahon G; Lin PC; Sierra-Rivera E; Oshinka H; Hallahan DE
Cancer Res; 2001 Mar; 61(6):2413-9. PubMed ID: 11289107
[TBL] [Abstract][Full Text] [Related]
8. The antiangiogenic agent neovastat (AE-941) inhibits vascular endothelial growth factor-mediated biological effects.
Béliveau R; Gingras D; Kruger EA; Lamy S; Sirois P; Simard B; Sirois MG; Tranqui L; Baffert F; Beaulieu E; Dimitriadou V; Pépin MC; Courjal F; Ricard I; Poyet P; Falardeau P; Figg WD; Dupont E
Clin Cancer Res; 2002 Apr; 8(4):1242-50. PubMed ID: 11948139
[TBL] [Abstract][Full Text] [Related]
9. Triple combination of irradiation, chemotherapy (pemetrexed), and VEGFR inhibition (SU5416) in human endothelial and tumor cells.
Bischof M; Abdollahi A; Gong P; Stoffregen C; Lipson KE; Debus JU; Weber KJ; Huber PE
Int J Radiat Oncol Biol Phys; 2004 Nov; 60(4):1220-32. PubMed ID: 15519795
[TBL] [Abstract][Full Text] [Related]
10. Blockade of EphA receptor tyrosine kinase activation inhibits vascular endothelial cell growth factor-induced angiogenesis.
Cheng N; Brantley DM; Liu H; Lin Q; Enriquez M; Gale N; Yancopoulos G; Cerretti DP; Daniel TO; Chen J
Mol Cancer Res; 2002 Nov; 1(1):2-11. PubMed ID: 12496364
[TBL] [Abstract][Full Text] [Related]
11. Tyrosine kinase inhibition of multiple angiogenic growth factor receptors improves survival in mice bearing colon cancer liver metastases by inhibition of endothelial cell survival mechanisms.
Shaheen RM; Tseng WW; Davis DW; Liu W; Reinmuth N; Vellagas R; Wieczorek AA; Ogura Y; McConkey DJ; Drazan KE; Bucana CD; McMahon G; Ellis LM
Cancer Res; 2001 Feb; 61(4):1464-8. PubMed ID: 11245452
[TBL] [Abstract][Full Text] [Related]
12. Antiangiogenic therapy targeting the tyrosine kinase receptor for vascular endothelial growth factor receptor inhibits the growth of colon cancer liver metastasis and induces tumor and endothelial cell apoptosis.
Shaheen RM; Davis DW; Liu W; Zebrowski BK; Wilson MR; Bucana CD; McConkey DJ; McMahon G; Ellis LM
Cancer Res; 1999 Nov; 59(21):5412-6. PubMed ID: 10554007
[TBL] [Abstract][Full Text] [Related]
13. Pharmacodynamic analysis of target inhibition and endothelial cell death in tumors treated with the vascular endothelial growth factor receptor antagonists SU5416 or SU6668.
Davis DW; Takamori R; Raut CP; Xiong HQ; Herbst RS; Stadler WM; Heymach JV; Demetri GD; Rashid A; Shen Y; Wen S; Abbruzzese JL; McConkey DJ
Clin Cancer Res; 2005 Jan; 11(2 Pt 1):678-89. PubMed ID: 15701856
[TBL] [Abstract][Full Text] [Related]
14. Down-modulation of monocyte transendothelial migration and endothelial adhesion molecule expression by fibroblast growth factor: reversal by the anti-angiogenic agent SU6668.
Zhang H; Issekutz AC
Am J Pathol; 2002 Jun; 160(6):2219-30. PubMed ID: 12057924
[TBL] [Abstract][Full Text] [Related]
15. The histone deacetylase inhibitor NVP-LAQ824 inhibits angiogenesis and has a greater antitumor effect in combination with the vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584.
Qian DZ; Wang X; Kachhap SK; Kato Y; Wei Y; Zhang L; Atadja P; Pili R
Cancer Res; 2004 Sep; 64(18):6626-34. PubMed ID: 15374977
[TBL] [Abstract][Full Text] [Related]
16. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
Ruggeri B; Singh J; Gingrich D; Angeles T; Albom M; Yang S; Chang H; Robinson C; Hunter K; Dobrzanski P; Jones-Bolin S; Pritchard S; Aimone L; Klein-Szanto A; Herbert JM; Bono F; Schaeffer P; Casellas P; Bourie B; Pili R; Isaacs J; Ator M; Hudkins R; Vaught J; Mallamo J; Dionne C
Cancer Res; 2003 Sep; 63(18):5978-91. PubMed ID: 14522925
[TBL] [Abstract][Full Text] [Related]
17. Vascular endothelial growth factor-mediated angiogenesis inhibition and postoperative wound healing in rats.
Roman CD; Choy H; Nanney L; Riordan C; Parman K; Johnson D; Beauchamp RD
J Surg Res; 2002 Jun; 105(1):43-7. PubMed ID: 12069500
[TBL] [Abstract][Full Text] [Related]
18. Simultaneous inhibition of the receptor kinase activity of vascular endothelial, fibroblast, and platelet-derived growth factors suppresses tumor growth and enhances tumor radiation response.
Griffin RJ; Williams BW; Wild R; Cherrington JM; Park H; Song CW
Cancer Res; 2002 Mar; 62(6):1702-6. PubMed ID: 11912143
[TBL] [Abstract][Full Text] [Related]
19. Regulation of the pro-angiogenic microenvironment by carboxyamido-triazole.
Oliver VK; Patton AM; Desai S; Lorang D; Libutti SK; Kohn EC
J Cell Physiol; 2003 Oct; 197(1):139-48. PubMed ID: 12942550
[TBL] [Abstract][Full Text] [Related]
20. Blockage of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation.
Gorski DH; Beckett MA; Jaskowiak NT; Calvin DP; Mauceri HJ; Salloum RM; Seetharam S; Koons A; Hari DM; Kufe DW; Weichselbaum RR
Cancer Res; 1999 Jul; 59(14):3374-8. PubMed ID: 10416597
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
